Premium
Combined treatment by chemotherapy and intravenous hyperalimentation in Japanese patients with advanced breast cancer
Author(s) -
Tominaga Takeshi,
Onodera Tokio,
Kitamura Masatsugu,
Kaneko Hajime,
Hayashi Kazuo,
Takahashi Isamu,
Itoh Ichiji
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19800815)46:4<642::aid-cncr2820460403>3.0.co;2-n
Subject(s) - medicine , cyclophosphamide , bone marrow suppression , chemotherapy , concomitant , refractory (planetary science) , breast cancer , endocrine system , toxicity , cancer , side effect (computer science) , bone marrow , surgery , oncology , hormone , physics , astrobiology , computer science , programming language
To treat advanced breast cancer that proved refractory to endocrine therapy or other forms of chemotherapy, we administered intravenous administration of adriamycin every 3–4 weeks, in principle, at a dose of 100 mg per 50 kg body weight (total dose, 300–400 mg). At the same time, 50 mg of cyclophosphamide was administered orally every day. In all cases, concomitant hyperalimentation treatment, which is considered an effective method for ameliorating the toxicity of the chemotherapeutic treatment, became necessary. Of 13 cases so treated, 10 showed significant improvement. It was almost impossible in general to administer such a dosage of adriamycin with cyclophosphamide to Japanese patients with advanced breast cancer, since the treatment brought on severe side effects such as depletion of oral intake and suppression of bone marrow function.